Prostate cancer

• 1. Introduction

  ›

  Prostate cancer kills around 350,000 people every year. One in eight men will be diagnosed with it in their lifetime, and one in forty will die of it. Yet most men who receive this diagnosis will outlive it entirely. Ninety-nine percent of those whose cancer is still confined to the prostate at diagnosis are alive more than ten years later. That gap between the feared word and the lived reality is at the heart of this story. How does a single disease carry such a wide range of fates? What separates the man who monitors a slow-growing tumor for decades from the one facing paralysis and bone pain? And how did medicine go from fumbling in the dark to Nobel Prizes and precision-guided radiopharmaceuticals? This documentary follows prostate cancer from its first recorded description in a London autopsy room to the cutting edge of castration-resistant treatment.

• 2. What the Prostate Does

  ›

  The prostate sits below the bladder in the male reproductive system, a gland whose location explains both what cancer there can do and why detecting it is so complicated. More than half of men over age 50 experience some form of urination problem. Most of the time, the culprit is benign prostatic hyperplasia, a non-cancerous enlargement that shares the same neighborhood as cancer but behaves very differently. Early prostate cancer typically produces no symptoms at all. Only as tumors advance do men notice blood in the urine or semen, erectile dysfunction, or a slow and weakened urine stream. The most dangerous tumors eventually spread to the pelvis, hips, spine, ribs, head, and neck, causing bone pain, fatigue, unexplained weight loss, and, if metastases compress the spinal cord, leg weakness or full paralysis. Around a quarter of those with metastatic prostate cancer suffer a bone fracture from the damage tumors inflict on surrounding tissue.

• 3. Finding Cancer Before It Speaks

  ›

  The typical man carries around 1 nanogram of prostate-specific antigen per milliliter of blood. PSA, a protein secreted by the prostate, rises whenever the gland is enlarged, whether from cancer or from benign causes. Men with PSA levels above 4 nanograms per milliliter face roughly a one-in-four chance of having prostate cancer and are commonly referred for biopsy. Above 10 nanograms per milliliter, more than half in that group will have the disease. PSA levels can fluctuate for unrelated reasons, so men with high readings are often asked to repeat the test four to six weeks later before any biopsy is ordered. Benign enlargement, prostate infection, recent ejaculation, and certain urological procedures can all push the number up; a class of drugs called 5-alpha-reductase inhibitors can push it down. Secondary tests have been developed to sharpen the picture. The Prostate Health Index measures a PSA fragment called minus-2proPSA, and the 4K score measures intact free PSA and kallikrein-2. Both aim to reduce the number of unnecessary biopsies by more accurately predicting which elevated PSA readings signal genuinely dangerous disease. Uptake of screening varies widely by geography: more than 80% of men in the United States and Western Europe are screened, compared to around 20% of men in Japan, and screening is rare in regions with a low Human Development Index.

• 4. Biopsy, Gleason, and Stage

  ›

  A definitive diagnosis requires a biopsy, typically taken by a needle guided through the rectum or perineum, with ten to twelve samples drawn from different regions of the prostate. A pathologist then grades the tissue under a microscope using the Gleason system, assigning numbers from 3 to 5 to different regions based on how much the cells have diverged from healthy prostate tissue. The two numbers covering the largest areas of the biopsy are added together, producing a Gleason score from 6 to 10. A score of 6 sits in grade group 1 and carries the best prognosis; a score of 9 or 10 falls in grade group 5. More than 95% of prostate cancers are adenocarcinomas, meaning they resemble gland tissue under the microscope. The remaining cases are largely squamous-cell or transitional cell carcinomas. Staging combines the Gleason grade group, PSA level, and imaging results under the American Joint Committee on Cancer's TNM system, producing a stage from I to IV. Stage I disease stays inside the prostate, carries a Gleason grade group of 1, and has a PSA below 10 nanograms per milliliter. Stage IV disease has spread to lymph nodes or distant organs. The United Kingdom uses a parallel five-tier Cambridge Prognostic Group system, with CPG1 matching AJCC stage I and CPG5 reserved for T4 tumors, Gleason grade group 5, or any two of the highest-risk CPG4 factors.

• 5. Treating the Confined Tumor

  ›

  At least half of men diagnosed with low-risk, localized prostate cancer never receive direct treatment. Active surveillance involves PSA tests roughly every six months, an annual digital rectal examination, and MRI or repeat biopsy every one to three years. Only when PSA levels, Gleason grade, or tumor size worsen does a more active intervention become necessary. Those who choose treatment receive either radiation therapy or radical prostatectomy; the two approaches produce similar rates of cancer control but differ in side effects. Intensity-modulated radiation therapy delivers doses greater than 80 gray to the prostate over several weeks of daily weekday sessions. Brachytherapy implants a radioactive source directly into the prostate in a single session, where it expends its radioactivity over the following months. Radiation can damage nearby organs, increasing the risk of subsequent bladder cancer and causing radiation proctitis, a condition that can produce diarrhea, bloody stools, fecal incontinence, and pain. Radical prostatectomy removes the prostate, seminal vesicles, and the end of the vas deferens. In wealthier countries, robotic-assisted surgery through small abdominal incisions has become the standard approach, producing shorter hospital stays and less blood loss than open surgery. The skill and experience of the individual surgeon are among the greatest determinants of outcome for both cancer control and side effects such as erectile dysfunction and urinary incontinence. After prostatectomy, PSA levels drop to very low or undetectable readings within two months. Up to half of those treated will eventually see PSA levels rise again, and those patients are often offered a further round of radiation aimed at the former tumor site, which reduces risk of further progression by 75%.

• 6. When Cancer Spreads

  ›

  Androgen deprivation therapy, sometimes called chemical castration, is the standard treatment once prostate cancer has spread beyond the gland. Prostate cells depend on androgens, particularly testosterone, to survive, and drugs that block testosterone synthesis or its action halt tumor growth in more than 95% of those treated. PSA levels return to normal in up to 70%. GnRH agonists such as leuprolide, goserelin, and triptorelin are typically given by injection monthly or less often, though they cause a brief testosterone surge at the start of treatment that can worsen symptoms in men with significant metastases. In those cases, GnRH antagonists like degarelix or relugolix are preferred. Reducing testosterone brings side effects of its own: hot flashes, loss of muscle mass and bone density, reduced sex drive, fatigue, personality changes, and an increased risk of diabetes, cardiovascular disease, and depression. Bone metastases are present in around 85% of those with metastatic prostate cancer and are the primary source of suffering and death at that stage. Patients can experience sudden, severe bursts of pain called breakthrough pain that resolve within around 15 minutes, faster than standard pain medications can act. Radium-223 and samarium-153-EDTMP, radioactive compounds that accumulate disproportionately in bone, can shrink bone tumors and reduce pain. Spinal cord compression from metastases occurs in up to 12% of those with metastatic disease, causing pain, weakness, numbness, and paralysis, treated with high-dose steroids, surgery, and radiotherapy.

• 7. Castration Resistance and the Final Lines

  ›

  Despite hormone therapy, metastatic prostate tumors eventually learn to grow without normal testosterone levels. This stage, castration-resistant prostate cancer (CRPC), is incurable and kills a majority of those who reach it. More than 70% of CRPC tumors carry mutations in the androgen receptor signaling pathway, compared to up to only 6% of castrate-sensitive metastatic tumors. The chemotherapy docetaxel was approved in 2004 as the first drug proven to extend survival in CRPC patients; in 2015 its use was broadened to those with castration-sensitive metastatic disease. Alongside docetaxel, antiandrogens such as enzalutamide, apalutamide, and darolutamide, as well as the testosterone production inhibitor abiraterone acetate, are used. Patients whose tumors express the protein PSMA may receive a radiopharmaceutical called Lu-177 PSMA, which binds to and destroys PSMA-positive cells. Those with defective DNA damage repair genes can benefit from pembrolizumab and PARP inhibitors, including olaparib, rucaparib, and niraparib. A cell therapy procedure called Sipuleucel-T removes the patient's own immune cells, engineers them to better target prostate cancer cells, and re-injects them. For tumors that resist docetaxel, a second-generation taxane drug called cabazitaxel provides another line of treatment. Deletions of the tumor suppressor gene PTEN appear in 12 to 17% of castrate-sensitive tumors but more than 40% of castrate-resistant ones, a genetic shift that reflects how thoroughly the disease reinvents itself under treatment pressure.

• 8. A Century of Breakthroughs

  ›

  A prostate mass was first formally described in 1817 by the English surgeon George Langstaff after the autopsy of a 68-year-old man who had died with lower-body pain and urinary symptoms. In 1853, London Hospital surgeon John Adams described another case and had a pathologist confirm it as cancer, establishing the first verified diagnosis. An 1893 survey found only 50 cases in all the medical literature. The disease's apparent rarity dissolved once prostate surgery for urinary obstruction became common around the turn of the 20th century; two studies from that era found cancer in as many as 10% of surgical specimens. The first deliberate surgical attempt to cure prostate cancer came in 1904, when Hugh H. Young performed a perineal prostatectomy at Johns Hopkins Hospital. In 1931, transurethral resection of the prostate replaced Young's method for relieving obstruction, and in 1945, Terence Millin described a retropubic approach that gave surgeons easier access to pelvic lymph nodes. Patrick C. Walsh refined that retropubic approach in 1983, showing how to spare the nearby nerves and preserve erectile function. The hormonal connection was clarified by Charles Huggins and Clarence V. Hodges in 1941, when they showed that surgical castration or oral estrogen improved prostate cancer symptoms. Huggins received the 1966 Nobel Prize in Physiology or Medicine for that discovery. Decades later, Andrzej W. Schally's work on GnRH led to the development of GnRH agonists that replicated the benefit of castration without the elevated clotting risk of estrogen therapy; Schally was awarded the 1977 Nobel Prize. Docetaxel's 2004 approval for CRPC was the first time any chemotherapy had been shown to extend survival in the disease, and from 2016 to 2020, more than 1.26 billion dollars was invested in prostate cancer research, representing around 5% of global cancer research funds.